EXO Biologics
ActiveSummary
The annual accounts of EXO Biologics for financial year 2025 show a net loss of 71% of the equity at the start of that year. The 2025 annual accounts show equity of €2.9m and a net result of -€2.3m. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 30% of 239 sector peers (NACE 72, financial year 2025). The company has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.9% (low).
Overview
Official details
Source: KBO- Status
- Active since 29-08-2019 Normal situation
- Registered office
- 47 active companies are registered at this address 4 started in the 12 months before. Source: KBO register, as of 3 November 2026.
- Activity
- Other research and development on natural sciences NACE 72109and 2 others
- Joint committee
- 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid · annual accounts 2025
- Establishment unit
- 2.349.033.855 4000 Liège, since 01-07-2023
- Financial year end
- 31 December
- Peppol
- Reachable
Board and ownership
- Biotech Management & ConsultingDaily manager · permanent representative WALLEMACQ Hugues
- FOIDART Jean Michel Francine Charles Simonne RenéDirector · since 11-09-2023
- Margarite LimitedDirector · since 11-09-2023 · permanent representative DALTON Colin Clive
- Holdings
- Shares in 1 company ExoXpert
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.9%
- Turnover
- €0
- ▼ 100%
- Loss
- €2.3m
- ▲ 12.7%
- Equity
- €2.9m
- ▼ 10.0%
- Total assets
- €11.7m
- ▼ 6.8%
- Employees on 31-12-2025
- 6
- ▼ 14.3%
Score breakdownraises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearLoss of €2.3m, the second in a row (financial year 2025)Liquidity: current ratio 1.30, cash €158,176, halvedlowers riskSector: Scientific research and development (NACE 72)Figures for financial year 2025 (filed on 16-07-2026)Show the evidence
Checked score
About 9 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro). It does better than 30% of them on solvency, 13% on liquidity, 10% on profitability and 34% on growth.
The bankruptcy probability was computed on 03-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 6 accounts on average 1 day after the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
- Risk: 6 loss-making years in a rowloss in financial year 2025 -€2.3m View
- Caution: Fewer staff in 2025from 15 FTE to 5.6 FTE ▼ 62.7% View
- Caution: Lower net result than 84% of companies in research and developmentsector median €3,198 · 237 companies -€2.3m View
- Board changedlatest change 16-06-2026 · 6 in office 1 joined · 1 left View
- Positive: Filed on time since financial year 2022accounts within the deadline every year 4 years View
Recent changes
- · Gazette deed 1 director appointed, 4 directors resigningChange of role: Pieter Van Rompay, from class A director to director · Resignations: Jo Bury, Hugues Wallemacq and Jean-Michel Foidart
- · Gazette deed Capital & shares · Amendment of the articles
- · Gazette deed Capital decrease of €5,132,867.76 to €5,181,820.14
Comparable companies
These companies have the same main activity as EXO Biologics: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €3.9m and €19m, founded between 2015 and 2023.
| Company | Total assets | Gross margin |
|---|---|---|
| EXO Biologics Liège | €11.7m | €0.4m |
| NEUVASQ BIOTECHNOLOGIES Charleroi | €7.2m | €0.6m |
| Minoryx Therapeutics BE Charleroi | €3.9m | €0.2m |
| Magnax Kortrijk | €18.7m | €0.1m |
| MAASH Anderlecht | €14.2m | €0.07m |
| AXITHRA Gent | €8.6m | €0.3m |
| DIABATIX Leuven | €4.1m | €1.0m |
Key facts about EXO Biologics
- What is the company number of EXO Biologics?
- The company number of EXO Biologics is 0732.982.379. The VAT number is the same number with BE in front: BE 0732.982.379.
- Where is EXO Biologics based?
- The registered office is at Boulevard de Patience et Beaujonc 3, 4000 Liège.Company details
- What does EXO Biologics do?
- According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
- What is the legal form of EXO Biologics?
- The legal form of EXO Biologics is Public limited company (NV).
- When was EXO Biologics founded?
- EXO Biologics was founded on 29-08-2019.
- Is EXO Biologics still active?
- Yes, EXO Biologics is an active enterprise in the KBO register.
- How many employees does EXO Biologics have?
- EXO Biologics had an average of 5.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does EXO Biologics fall under?
- In its 2025 annual accounts, EXO Biologics states joint committee 207 (Paritair Comité voor de bedienden uit de scheikundige nijverheid).
- What is the turnover of EXO Biologics?
- The turnover of EXO Biologics was €0 in financial year 2025, according to the filed annual accounts.
- Is EXO Biologics profitable?
- In financial year 2025, EXO Biologics made a loss of €2.3m.
- Where can I find the annual accounts of EXO Biologics?
- EXO Biologics filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of EXO Biologics due?
- EXO Biologics must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.